The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…